SAN CARLOS, Calif., Nov. 22, 2016 /PRNewswire/ -- Natera (NASDAQ :NTRA ), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the 28th Annual Piper Jaffray Health Conference in New York on Tuesday, November 29, 2016 at 4:00 p.m. ET. Matthew Rabinowitz, Ph.D., CEO of Natera, will discuss the Company's financial results, business activities and financial outlook.
Natera will offer a live audio webcast of the presentation that may be accessed on the Investor Relations section of the Company's website at investor.natera.com or by using the following link: http://edge.media-server.com/m/p/hzenrd72. A replay of the webcast also will be archived and available for 30 days after the presentation.
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system.
Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier test to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to detect for common chromosomal anomalies in a fetus as early as nine weeks of gestation.
Each test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test.
These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.
Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit http://www.natera.com and connect on Twitter and Facebook.
SOURCE Natera, Inc.